Therapeutic | Dostarlimab |
Target | PDCD1 |
Heavy Chain | EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYDMSWVRQAPGKGLEWVSTISGGGSYTYYQDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCASPYYAMDYWGQGTTVTVSS |
Light Chain | DIQLTQSPSFLSAYVGDRVTITCKASQDVGTAVAWYQQKPGKAPKLLIYWASTLHTGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQHYSSYPWTFGQGTKLEIK |
100% seqID Fv Structure | None |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G4 |
Highest Clinical Trial (June '19) | Phase-III |
Estimated Status (June '19) | Active |
Recorded Developmental Technology | na |
INN Year Proposed | 2018 |
INN Year Recommended | 2019 |
Companies Involved | AnaptysBio, European Network of Gynaecological Oncological Trial Groups, GlaxoSmithKline, TESARO |
Conditions Approved | na |
Conditions Active | Fallopian tube cancer, Ovarian cancer, Peritoneal cancer, Endometrial cancer, Non-small cell lung cancer, Solid tumours |
Conditions Discontinued | na |
Notes |